Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether-lumefantrine plus ruxolitinib in induced blood-stage malaria
ACTRN12621000866808Phase 2Recruiting
- Sponsor
- QIMR Berghofer Medical Research Institute
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in malaria comparing Riamet + Jakavi with Riamet + placebo (2 arms). Primary endpoint: Composite safety outcome. Started Jun 2021; status: recruiting.
02
Drugs
ruxolitinibartemether + lumefantrine
03
Conditions
malaria
Beyond the preview
Go deeper on ACTRN12621000866808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000866808.